Dashboard
Manage Tickers

IMTX Immatics N.V.

Nasdaq immatics.com


$ 9.51 $ 0.00 (0 %)    

Wednesday, 12-Nov-2025 07:39:07 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 625.15 $ 0.00 (0 %)
DIA $ 480.53 $ 0.00 (0 %)
SPY $ 685.23 $ 0.00 (0 %)
TLT $ 89.83 $ 0.00 (0 %)
GLD $ 380.00 $ 0.00 (0 %)
$ 9.19
$ 8.98
$ 8.40 x 5
$ 9.94 x 343
-- - --
$ 3.30 - $ 11.25
476,371
na
1.12B
$ 1.03
$ 70.91
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immatics-achieves-clinical-proof-of-concept-for-tcer-pipeline-ima402-prame-30-corr-ima401-magea48-up-to-29-corr-initiates-phase-1b-and-plans-combo-in-sqnsclc
Immatics Achieves Clinical Proof-Of-Concep...
11/12/2025 12:20:21

immatics-presents-updated-data-from-16-patients-with-metastatic-uveal-melanoma-treated-with-anzu-cel-prame-cell-therapy-at-esmo-2025-presidential-symposium
Immatics Presents Updated Data From 16 Pat...
10/20/2025 14:32:34

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanom...

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/10/2025 21:06:24

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 12:09:25

immatics-appoints-venkat-ramanan-as-cfo-effective-immediately-succeeding-arnd-christ
Immatics Appoints Venkat Ramanan As CFO, E...
10/01/2025 11:06:40

guggenheim-initiates-coverage-on-immatics-with-buy-rating-announces-price-target-of-16
Guggenheim Initiates Coverage On Immatics ...
09/18/2025 13:04:20

Guggenheim analyst Paul Jeng initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target of $16.

fabrinet-adecoagro-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Fabrinet, Adecoagro And Other Big Stocks M...
08/19/2025 10:21:33

immatics-q2-2025-cash-and-cash-equivalents-as-well-as-other-financial-assets-of-5605m-cash-reach-into-2h-2027
Immatics Q2 2025 Cash And Cash Equivalents...
08/13/2025 11:10:30

immatics-q2-eps-068-misses-038-estimate-sales-5500m-miss-14270m-estimate
Immatics Q2 EPS $(0.68) Misses $(0.38) Est...
08/13/2025 11:09:49

reported-saturday-immatics-presents-expanded-ima203-prame-cell-therapy-results-at-asco-durable-objective-responses-in-91-of-patients-and-favorable-safety-profile
Reported Saturday, Immatics Presents Expan...
06/02/2025 08:52:23

Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demon...

deutsche-bank-initiates-coverage-on-immatics-with-buy-rating-announces-price-target-of-10
Deutsche Bank Initiates Coverage On Immati...
05/28/2025 18:29:48

Deutsche Bank analyst James Shin initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target o...

immatics-q1-eps-035-misses-033-estimate-sales-1954m-beat-1542m-estimate
Immatics Q1 EPS $(0.35) Misses $(0.33) Est...
05/13/2025 11:24:25

Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by...

immatics-q1-sales-2010m-beat-1396m-estimate
Immatics Q1 Sales $20.10M Beat $13.96M Est...
05/13/2025 11:12:06

cantor-fitzgerald-reiterates-overweight-on-immaticsto-overweight
Cantor Fitzgerald Reiterates Overweight on...
04/01/2025 15:06:39

Cantor Fitzgerald analyst Eric Schmidt reiterates Immatics (NASDAQ:IMTX) from Overweight to Overweight.

immatics-fy-2024-gaap-eps-014-beats-065-estimate-revenue-from-collaboration-agreements-of-15584m-vs-54m-yoy
Immatics FY 2024 GAAP EPS €(0.14) Beats €(...
03/27/2025 11:10:39

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
01/03/2025 21:05:52

Core News & Articles
Reported Friday, December 13, 2024, Bristo...
12/16/2024 14:42:20

On December 12, 2024, Bristol Myers Squibb ("BMS") notified Immatics N.V.

b-of-a-securities-maintains-buy-on-immatics-lowers-price-target-to-15
B of A Securities Maintains Buy on Immatic...
11/19/2024 17:29:31

B of A Securities analyst Alex Stranahan maintains Immatics (NASDAQ:IMTX) with a Buy and lowers the price target from $16 to...

reported-earlier-immatics-prices-150m-public-offering-of-1625m-common-shares-at-925share
Reported Earlier, Immatics Prices $150M Pu...
10/11/2024 06:24:15

why-is-cancer-focused-immatics-stock-trading-lower-on-thursday
Why Is Cancer-Focused Immatics Stock Tradi...
10/10/2024 17:33:31

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was obs...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION